摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2-Dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile | 205818-52-6

中文名称
——
中文别名
——
英文名称
2,2-Dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile
英文别名
2,2-dimethyl-3-oxo-4H-1,4-benzoxazine-6-carbonitrile
2,2-Dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile化学式
CAS
205818-52-6
化学式
C11H10N2O2
mdl
MFCD20039828
分子量
202.213
InChiKey
KEFFHGHKFDZMSO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    97-99 °C(Solv: ethyl ether (60-29-7); hexane (110-54-3))
  • 沸点:
    381.2±42.0 °C(Predicted)
  • 密度:
    1.28±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.272
  • 拓扑面积:
    62.1
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF<br/>[FR] DÉRIVÉ TRICYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 三环类衍生物及其制备方法和用途
    申请人:[en]ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.;[zh]浙江海正药业股份有限公司
    公开号:WO2023165438A1
    公开(公告)日:2023-09-07
    本发明涉及一种取代的三环类衍生物、其制备方法及含有该衍生物的药物组合物在医药上的应用。具体而言,本发明涉及一种通式(I)所示的取代的三环类衍生物、其制备方法及其可药用的盐,以及它们作为治疗剂,特别是SOS1抑制剂的用途,其中通式(I)中的各取代基的定义与说明书中的定义相同。
  • Synthesis, biological activity and conformational study of 1,4-benzoxazine derivatives as potassium channel modulators
    作者:Giuseppe Caliendo、Paolo Grieco、Elisa Perissutti、Vincenzo Santagada、Antonello Santini、Stefania Albrizio、Caterina Fattorusso、Aldo Pinto、Raffaella Sorrentino
    DOI:10.1016/s0223-5234(99)80020-8
    日期:1998.12
    With the aim of discovering new molecules with K+-channel activating properties, we have synthesized derivatives of cromakalim (CRK), an important molecule which shows specific affinity towards K+ channels, by replacing the benzopyrane ring of this reference compound with a 1,4-benzoxazine moiety. A different number of substituents showing a good discrimination between hydrophobic and electronic properties have been inserted at the 6-position of the 1,4-benzoxazine ring. We describe here the synthesis and discuss the solid state conformation of these new molecules. When tested on rat aorta ring precontracted with phenylephrine, two compounds (2c and 2d) showed a concentration-dependent relaxation similar to that measured for cromakalim but less potent than this reference drug. (C) Elsevier, Paris.
  • Synthesis by microwave irradiation of a substituted benzoxazine parallel library with preferential relaxant activity for guinea pig trachealis
    作者:Giuseppe Caliendo、Elisa Perissutti、Vincenzo Santagada、Ferdinando Fiorino、Beatrice Severino、Donatella Cirillo、Roberta d’Emmanuele di Villa Bianca、Laura Lippolis、Aldo Pinto、Raffaella Sorrentino
    DOI:10.1016/j.ejmech.2004.05.003
    日期:2004.10
    An efficient, facile, and practical parallel combinatorial synthesis of substituted-benzoxazines under microwave irradiation was described. The procedure involved the use of a microwave oven especially designed for organic synthesis suitable for parallel synthesis of solution libraries. A demonstration 19-membered library of substituted N,N-dimethyl- and N-methyl-benzoxazine amide derivatives, structurally related to the potassium channel opener cromakalim, was generated by both conventional and microwave procedures, achieving a reduction from 7 h to 30-36 min in library generation time for the microwave approach. All the synthesized compounds were tested using the in vitro models of rat aorta and guinea pig trachea rings pre-contracted with phenylephrine and carbachol, respectively. All N,N-dimethyl amide derivatives showed a relaxant activity higher on guinea pig trachea rings than on rat aorta rings. (C) 2004 Elsevier SAS. All rights reserved.
  • Heterobicyclic metalloprotease inhibitors
    申请人:Steeneck Christoph
    公开号:US20070155738A1
    公开(公告)日:2007-07-05
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
  • Heterobicyclic Metalloprotease Inhibitors
    申请人:STEENECK Christoph
    公开号:US20090312312A1
    公开(公告)日:2009-12-17
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
查看更多